Trial
NCT01230827
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Janssen Research & Development, LLC
Collaborators
Schering-Plough
Condition
Juvenile Idiopathic Arthritis
Intervention
CNTO 148 (Golimumab)
Why stopped
Trial has failed to meet primary - and major secondary endpoints
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-04-04